Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Haylor, J. L.
Right arrow Articles by Morcos, S. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haylor, J. L.
Right arrow Articles by Morcos, S. K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2001) 16: 1336-1337
© 2001 European Renal Association-European Dialysis and Transplant Association

Personal Opinion

An oral ETA-selective endothelin receptor antagonist for contrast nephropathy?

John L. Haylor1, and Sameh K. Morcos2

1 Sheffield Kidney Institute, 2 Department of Diagnostic Imaging, Northern General Hospital, Sheffield, UK

Introduction

Endothelin (ET) has been proposed to play an important mediator role in contrast media (CM) nephropathy [1,2]. The first prevention trial in CM nephropathy using an anti-endothelin agent was undertaken at Dukes Medical Center in North Carolina employing SB 209670, an injectable, non-selective ET-receptor antagonist [3]. The choice of SB 209670 was surprising, since in animal studies it had failed to produce significant inhibition of even the acute fall in GFR induced by contrast agents [4,5] and its effect in CM nephropathy had not been reported. Treatment with SB 209670, however, increased, rather than . . . [Full Text of this Article]

Was SB 209670 present in the circulation when CM nephropathy was determined?

SB 209670 increases the plasma ET-1 concentration

Could SB 209670 have prevented a fall in GFR mediated by endothelin?

SB 209670 and systemic blood pressure

Consequence of the SB 209670 human CM nephropathy trial

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?